Home Cart 0 Sign in  
X

[ CAS No. 294-90-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 294-90-6
Chemical Structure| 294-90-6
Chemical Structure| 294-90-6
Structure of 294-90-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 294-90-6 ]

Related Doc. of [ 294-90-6 ]

Alternatived Products of [ 294-90-6 ]

Product Details of [ 294-90-6 ]

CAS No. :294-90-6 MDL No. :MFCD00066281
Formula : C8H20N4 Boiling Point : -
Linear Structure Formula :- InChI Key :QBPPRVHXOZRESW-UHFFFAOYSA-N
M.W : 172.27 Pubchem ID :64963
Synonyms :
Chemical Name :1,4,7,10-Tetraazacyclododecane

Calculated chemistry of [ 294-90-6 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 0
Fraction Csp3 : 1.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 4.0
Num. H-bond donors : 4.0
Molar Refractivity : 65.32
TPSA : 48.12 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -9.03 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.81
Log Po/w (XLOGP3) : -2.36
Log Po/w (WLOGP) : -3.16
Log Po/w (MLOGP) : -0.83
Log Po/w (SILICOS-IT) : 0.31
Consensus Log Po/w : -0.85

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : 0.58
Solubility : 653.0 mg/ml ; 3.79 mol/l
Class : Highly soluble
Log S (Ali) : 1.89
Solubility : 13300.0 mg/ml ; 77.1 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : -2.31
Solubility : 0.85 mg/ml ; 0.00493 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.01

Safety of [ 294-90-6 ]

Signal Word:Danger Class:8
Precautionary Statements:P501-P273-P260-P270-P264-P280-P391-P362+P364-P303+P361+P353-P301+P330+P331-P301+P312+P330-P304+P340+P310-P305+P351+P338+P310-P405 UN#:3259
Hazard Statements:H302+H312-H314-H410 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 294-90-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 294-90-6 ]
  • Downstream synthetic route of [ 294-90-6 ]

[ 294-90-6 ] Synthesis Path-Upstream   1~17

  • 1
  • [ 294-90-6 ]
  • [ 5460-29-7 ]
Reference: [1] Patent: US2014/154815, 2014, A1, . Location in patent: Page/Page column
  • 2
  • [ 79-11-8 ]
  • [ 294-90-6 ]
  • [ 60239-18-1 ]
YieldReaction ConditionsOperation in experiment
183 g With potassium hydroxide In water at 80℃; for 24 h; To the three-necked flask was added 1,4,7,10-tetraazacyclododecane (100 g, 0.58 mol)10 ml of deionized water, stirred, 30percent KOH solution was added dropwise,The pH was adjusted to 8.5 and then chloroacetic acid (263 g, 2.78 mol) was added,And then 30percent KOH solution to adjust the pH to 8.5,Heated to 80 ° C for 24 h, during which the pH was maintained between 8.5 and 9.After the reaction, cooling, adding concentrated hydrochloric acid to adjust the pH to 2, a white precipitate produced, filtered. The filter cake was recrystallized from a water-ethanol solution and the resulting crystals were washed with ethanol, ether, dried,183 g of DOTA crystals was obtained in a yield of 78percent.
Reference: [1] Journal of Labelled Compounds and Radiopharmaceuticals, 2003, vol. 46, # 3, p. 197 - 209
[2] Dalton Transactions, 2016, vol. 45, # 23, p. 9553 - 9564
[3] Patent: WO2014/114664, 2014, A1, . Location in patent: Page/Page column 28-29
[4] Patent: WO2015/117911, 2015, A1, . Location in patent: Paragraph 0081; 0082; 0083; 0084
[5] Patent: CN104447598, 2017, B, . Location in patent: Paragraph 0096; 0098; 0099
  • 3
  • [ 3926-62-3 ]
  • [ 294-90-6 ]
  • [ 60239-18-1 ]
Reference: [1] Patent: WO2017/103258, 2017, A1, . Location in patent: Page/Page column 9; 10; 11
  • 4
  • [ 294-90-6 ]
  • [ 60239-18-1 ]
Reference: [1] Chemical Communications, 2013, vol. 49, # 6, p. 564 - 566
[2] Patent: KR101851981, 2018, B1,
  • 5
  • [ 50-00-0 ]
  • [ 294-90-6 ]
  • [ 91987-74-5 ]
Reference: [1] Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation), 1984, vol. 33, p. 777 - 782[2] Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1984, # 4, p. 844 - 849
  • 6
  • [ 683-57-8 ]
  • [ 294-90-6 ]
  • [ 157599-02-5 ]
YieldReaction ConditionsOperation in experiment
66% With triethylamine In ethanol at 80℃; for 4 h; To a 100 mL round bottom flask fitted with a reflux condenser and stir bar was added 1.4696 g Cyclen (8.5 mmol). 5.44 11 g of 2-bromoacetamide (39.4 mmol, 4.6 eq) was added with 4.5748 g triethylamine (44.9 mmol, 5.3 eq) in 30 mL absolute ethanol. The contents were refluxed for 4 hours at 80 °C, after which time a white precipitate formed in the flask. After cooling to room temperature, the precipitate was decanted and placed in a 250 mL round bottom flask, then dissolved in 200 mL of hot 80 percent ethanol/20 percent water. The volume was reduced by approximately 30 percent on a roto-evaporator, then placed in the refrigerator overnight to produce white crystals. The remaining solvent was removed by filtration and the crystals were transferred to a 50 mL round bottom flask to dry on a Schlenk line under vacuum for several hours (66 percent yield). ESI-MS: m/z = 401.3 (100 percent), 402.3 (15 percent) [M + H]+; 423.4 (25 percent), 424.4 (< 10 percent) [M + Na]+. 1H NMR (500 MHz, D20), ppm: 3.02 (s, amide pendent CH28H), 2.57 (s, Cyclen ring 16 H). 13C NMR (125 MHz, D20), ppm: 174.07 (carbonyl C),55.86 (amide CH2), 50.42 (ring CH2).
Reference: [1] Patent: WO2015/38943, 2015, A1, . Location in patent: Page/Page column 51; 52
[2] Angewandte Chemie, 1994, vol. 106, # 7, p. 824 - 826
[3] Helvetica Chimica Acta, 2005, vol. 88, # 5, p. 923 - 935
  • 7
  • [ 294-90-6 ]
  • [ 79-07-2 ]
  • [ 157599-02-5 ]
Reference: [1] Journal of the American Chemical Society, 1995, vol. 117, # 25, p. 6698 - 6707
[2] Journal of the Chemical Society, Chemical Communications, 1994, # 8, p. 1007 - 1008
  • 8
  • [ 24424-99-5 ]
  • [ 294-90-6 ]
  • [ 175854-39-4 ]
YieldReaction ConditionsOperation in experiment
80% With triethylamine In chloroform at 20℃; A solution of di-tert-butyl dicarbonate (1.77 g, 8.12 mmol) in chloroform (10 mL) was added slowly via addition funnel to a solution of cyclen (7, 0.51 g, 2.90 mmol) and triethylamine (1.25 mL, 8.99 mmol) in chloroform (40 mL) at rt. The reaction mixture was stirred at rt overnight and then concentrated through rotary evaporation. The resulting residue was purified by column chromatography over silica gel with gradient elution from ethyl acetate to 5percent methanol/dichloromethane to yield the product as a white solid (1.02 g, 80percent). Characterizations matched previous reports.61
72% With triethylamine In chloroform at 20℃; for 24 h; Molecule A can be prepared by slowly, i.e. within 3 hours, adding a solution of di-tert-butyl dicarbonate (7.9 g, 36 mmol) in CHCl3 (100 mL, passed through Al2O3) to a solution of cyclen (2.2 g, 13 mmol) and triethylamine (5.5 mL, 39 mmol) in CHCl3 (120 mL) at room temperature. The reaction mixture is stirred for 24 hours at room temperature, and the organic solvent is removed under reduced pressure. The remaining residue is purified by silica gel column chromatography (hexanes/AcOEt) to provide molecule A as a colourless, amorphous solid (4.4 g, 72percent)[ E. Kimura, J. Am. Chem. Soc., 1997, 199, 3068-3076].The tri-BOC protected molecule A (15.2 g) is then dissolved in 20 mL of acetonitrile, after which 19 mL of diisopropylethylamine and 7.9 g of benzylbromoacetate in 10 mL acetonitrile are added. The solution is heated up to 60-65° C. and stirred overnight under an argon atmosphere. The mixture is then concentrated by evaporation of the solvent and dissolved in dichloromethane. The solution is washed with 1 M NaOH. The organic layer is dried with Na2SO4 and thereafter reduced by evaporation and co-evaporation with toluene. The pure product, molecule B, is isolated by silica column chromatography using hexane/ethyl acetate(1/1) as eluent. The yield is about 90percent.Molecule B (6.22 g) is dissolved in 60 mL dichloromethane and 60 mL trifluoracetic acid (TFA). The solution is stirred under a nitrogen atmosphere. After 3 hours the solvents are evaporated and another portion of TFA (40 mL) is added. After 2 hours of further stirring the TFA is evaporated and the remaining mixture is co-evaporated twice with toluene, leaving the crude TFA-salt of molecule C as an oil, of which then 10 g is used in a following step without further purification. The oil is dissolved and stirred in 45 mL DMF and 31 mL diisopropylethylamine. Then, 4.7 g bromo acetamide is added and the mixture is stirred for two days at 50° C., during which time a precipitate is developed. The mixture is brought in 600 mL ether, is stirred and the brown precipitate is isolated by filtration and washing with ether. The solid is then washed four times with portions of 25 mL of 25percent NH3 solutions in water and finally with 30 mL of water. Drying under vacuum at 40° C. results in a white solid product of molecule D (yield=85percent).Molecule D (1.7 g) is then hydrogenated at 70 psi overpressure in 100 mL water using Pd/C (10percent) as catalyst. The mixture is filtered over celite, the celite is washed with some water and the filtrate is freeze dried and then dried over P2O5 in vacuum to afford 1.1 gram of a fine white hygroscopic powder of molecule E.For the coupling of molecule E to the carrier, in the example given to a PPI dendrimer, the amide coupling agent HBTU (O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate) is used. The coupling of the paramagnetic complex to the dendrimer is illustrated in FIG. 5. For convenience, the dendrimers are denoted as circles. The dendrimers used are commercially available poly(propylene imine) (PPI) dendrimers (from Aldrich under the name DAB-Am-X or from SyMO-Chem) with a diaminobutane (DAB) derived core. The most used name for those dendrimers is DAB-Am-X, wherein X refers to the number of surface amino groups. In this synthesis, DAB-Am-4 and DAB-Am-16 have been used in order to respectively obtain a DOTAM-G1 complex and a DOTAM-G3 complex. The formation of DOTAM-G1 and DOTAM-G3 is similar, only the value for the number n of end groups is different, i.e. for DOTAM-G1 n=4 and for DOTAM-G3 n=16.For the coupling of molecule E to the G1 PPI dendrimer, 0.39 mL diisopropylethylamine is added to a mixture of 312 mg HBTU in 3 mL dry DMF. Molecule E (300 mg) is added, the mixture is stirred until a clear solution is acquired. This may take about 5 to 10 minutes. Subsequently, 60 mg DAB-Am-4 in 3 mL DMF is added. The mixture is stirred overnight under an inert atmosphere, after which it is dropped into 150 mL of ether. The sticky precipitate is taken up in a small amount of methanol and precipitated into ether giving a white solid, that is again precipitated from methanol into ether. Finally, the solid is dissolved in methanol and eluted over an anion exchange column (Dowex OH-). Evaporation of the solvent gave about 200 mg of product, which in the further synthesis will be called molecule II.For the coupling of molecule E to the G3 PPI dendrimer, 0.25 mL diisopropylethylamine is added to a mixture of 164 mg HBTU in 1 mL dry DMF. Molecule E (172 mg) is added and the mixture is stirred until a clear solution is acquired. This may take about 5 to 10 minutes. The third generation PPI-dendrimer DAB-Am-16 (41 mg) in 1 mL dry DMF is then added and the solution is stirred overnight under an inert atmosphere of nitrogen. The mixture is poured into 40 mL of stirred ether giving a precipitate; the ether is replaced by another portion of ether (washing step), and the precipitate is dried. Finally, the precipitate is dissolved in water and triethylamine and this solution is dialysed using a membrane with a molecular weight cut-off of 1000 and using 1.2 L of water and 20 mL of triethyl amine as washing solvent. After overnight dialysis, the washing solution is replaced by 1.2 L of water and dialysis is continued for another 24 hours. Freeze drying of the solution in the dialysis tube gave ca. 200 mg of a fluffy white product, which in the further synthesis will be called molecule III.FIG. 6 illustrates the coupling of molecule E to an aliphatic/aromatic tail. A similar synthetic and purification procedure as used for molecule II may be applied, using N-carbobenzoxy-1,5-diaminopentane (mono Cbz-protected 1,5-pentyldiamine) as amine starting product. The resulting product will in the further synthesis be referred to as molecule IV.A last step in the synthesis is the complexation with Yb3+ ions. For the formation of the Yb-DOTAM-G1 complex, a solution of 0.1 mmol YbCl3 in 5 mL water is added dropwise to a stirring solution of 49 mg (0.1 mmol) of molecule II in 8 mL water. Subsequently, the solution is heated up to 60° C. for 2 hours while stirring, meanwhile maintaining a pH of 7 to 8 by adding small drops of NH4OH. The solution is dialysed for 24 hours using a membrane with a molecular weight cut-off of 500 and running water as washing solvent. Freeze drying of the solution yields a white powder in a yield of 80percent.For the formation of the Yb-DOTAM-G3 complex the complexation procedure is similar as for the Yb-DOTAM-G1 complex, but now molecule III is used instead of molecule II.For the formation of the Yb-DOTAM-tail complex, the complexation procedures is also similar as for the Yb-DOTAM-G1 complex but now molecule IV is used instead of molecule II and a dialysis membrane with a molecular weight cut-off of 100 is used.It has to be understood that the above-described synthesis may also be used to form other CEST contrast agents comprising, for example, other lanthanides than Yb or derivatives of the DOTAM chelating ligand.
72% With triethylamine In chloroform at 0 - 20℃; Inert atmosphere To a solution of cyclen (S4, 1.73 g, 10.0 mmol) and triethylamine (4.20 mL, 30.1 mmol)in CHCI3 (120 mL, freshly passed through A1203 (activated, neutral, Brockmann I)) at 0°C was added dropwise a solution of di-tert-butyl dicarbonate (6.55 g, 30.0 mmol) inCHCl (100 mL, freshly passed through A1203 (activated, neutral, Brockmann I)) under N2. After the addition was complete, the resulting solution was allowed to warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by flash column chromatography (silica gel, EtOAc:hexane = 3:2 ramping to EtOAc) to give S6 as a white foam (3.41 g, 72percent).RF (EtOAc:hexane = 4:1) 0.63. IR vmax/cm1 3313, 2974, 2931, 2818, 1679, 1463, 1412,365, 1313, 1247, 1156, 1 046, 771, 736. 1H NMR (400 MHz, CDCI3) 5 1.45 (5, 1 8H, 2 x C(CH3)3), 1.47 (5, 9H, C(CH3)3), 2.78-2.92 (m, 4H, CH2NHCH2), 3.16-3.34 (m, 6H),3.34-3.50 (m, 2H), 3.55-3.75 (m, 4H) (total 12H, 3 x CH2N(Boc)CH2) (one secondary amine proton signal (NH) not observed). ‘3C NMR (100 MHz, CDCI3) 5 28.1, 28.2, 28.3,28.4, 28.5, 44.7, 45.7, 48.8, 49.2, 50.3, 50.8, 78.9, 79.1, 155.1, 155.4 (eight carbon signals overlapping or obscured). MS (ESI) m/z 472.9 ([M+H], 27percent), 495.0 ([M+Na], 99percent), 967.1 ([2M+Na], 100percent). The spectroscopic data were in agreement with those in the literature.3739
68% With triethylamine In chloroform at 20℃; for 6 h; In a 200 mL round bottom flask, 1,4,7,10-tetraazacyclododecane (2 g), chloroform (50 mL), three Ethylamine (11.2 mL, 7.2 eq) was stirred at room temperature. Dissolve 30 mL of di-tert-butyl dicarbonate (6.87 g, 2.7 eq) The chloroform solution was added dropwise to the system at room temperature, and after 6 hours of reaction, TLC dot plate detection reaction is over, Condensed by vacuum distillation, and purified by column chromatography (developing solvent: petroleum ether: ethyl acetate = 1:1) 1,4,7,10-tetraazacyclododecyl-1,4,7-tricarboxylic acid tri-tert-butyl ester (3.73 g) was obtained. The product was obtained as a colorless oil, yield 68percent.
57% With diisopropylamine In chloroform for 12 h; Inert atmosphere Di-tert-butyl dicarbonate (16.5 g, 0.076 mol) in chloroform (100 mL) was added dropwise to a chilled mixture of 1 ,4,7,10-tetraazacyclododecane (5.0 g, 0.029 mol) and diisopropylamine (15 mL, 0.087 mol) in chloroform (200 mL) over a period of three hours. The reaction was then stirred overnight under an atmosphere of nitrogen. The reaction was concentrated, brought up in ethyl acetate (600 mL) and washed with saturated sodium bicarbonate (200 mL), followed by one wash of monobasic potassium phosphate (200 mL of 1 M) and brine (200 mL). The ethyl acetate was dried over sodium sulfate, filtered and concentrated. The crude reaction was purified using flash chromatography (4:1 ethyl acetate :hexanes) to yield a white solid (7.84 g, 57percent). 1H NMR (400 MHz, CDCI3) δ 3.67-3.52 (br, 4H), 3.46-3.14 (m, 8H), 2.88-2.72 (br, 4H), 1 .44 (s, 9H), 1 .42 (s, 18H); 13C NMR (100 MHz, CDCI3) δ 155.4, 79.2, 79.1 , 50.8, 49.3, 49.3, 48.7, 45.8, 44.8, 28.5, 28.3; LRMS (ESI): m/z [M+H]+ calc'd for C23H45N406+ 473.33, found 473.33.
57% With diisopropylamine In chloroform at 0 - 20℃; Inert atmosphere Di-tert-butyl dicarbonate (16.5 g, 0.076 mol) in chloroform (100 mL) was added dropwise to a chilled mixture (0 °C) of 1,4,7,10-tetraazacyclododecane (5.0 g, 0.029 mol) and diisopropylamine (15 mL, 0.087 mol) in chloroform (200 mL), over a period of three hours. The reaction was then stirred overnight under an atmosphere of nitrogen at room temperature. The reaction was concentrated, brought up in ethyl acetate (600 mL) and washed with saturated sodium bicarbonate (200 mL), followed by one wash of monobasic potassium phosphate (200 mL of 1M) and brine (200 mL). The ethyl acetate was dried over sodium sulfate, filtered and concentrated. The crude reaction was purified using flash chromatography (80 percent ethyl acetate, 20percent hexanes) to yield a white solid (7.84 g, 57percent).1H NMR (400 MHz, CDCl3) δ 1.37-1.50 (m, 27H, 3 x Boc (CH3)3), 2.79-2.89 (br, 4H, 2 x cyclen CH2), 3.17-3.47 (m, 8H, 4 x cyclen CH2), 3.54-3.70 (br, 4H, 2 x cyclen CH2);13C NMR (100 MHz, CDCl3) δ 28.61, 28.80, 45.10, 46.11, 48.97, 49.59, 50.00, 51.12, 79.34, 79.46, 70.60, 155.53, 155.74, 155.92; LRMS (ESI): m/z [M+H]+calc’d for C23H45N4O6+473.33, found 473.33.
56% at 20℃; for 18 h; A solution of di-tert-butyl dicarbonate (6.08 g, 27.86 mmol) in CH2Cl2 (100 ml) was added dropwise to a stirred solution of cyclen (2.00 g, 11.61 mmol) in CH2Cl2 (300 ml).The mixture was stirred at room temperature for 18 h. The solvent was removed under reduced pressure to yield a transparent oil, which was purified by <n="32"/>column chromatography on silica (gradient elution: 100percent CH2Cl2 - 5 percent MeOH/CH2Cl2, Rf = 0.29 10percent MeOH/CH2Cl2) to afford the title compound as a white crystalline solid (3.08 g, 6.51 mmol, 56 percent). δH (CDCI3, 300 MHz) 1.42 (18H, s, 3 x tBu), 1.44 (9H, s, tBu), 2.81 (4H, br s, cyclen 2 x CH2), 3.28 (8H, br s, cyclen 4 x CH2), 3.60 (4H, br s, cyclen 2 x CH2). δc (CDCI3, 75 MHz) 28.9 (tBu), 29.0 ^Bu), 46.1 (cyclen CH2), 49.9 (cyclen CH2), 51.2 (cyclen CH2), 79.4 (C), 79.6 (C), 155.8 (C=O), 156.0 (C=O). MS (ES+) m/z 473.4 (100 percent, [M + H]+).
56% at 20℃; A solution of di-te/t-butyl dicarbonate (6.08 g, 27.8 mmol) in anhydrous CH2CI2 (100 ml) was added dropwise to a stirred solution of cyclen (2.00 g, 11.61 mmol) in anhydrous CH2CI2 (300 ml). The reaction mixture was stirred at room temperature, for 18 h. The solvent was removed under reduced pressure to afford a transparent oil. The crude material was purified by column chromatography on silica (gradient elution: CH2CI2 to 5 percent CH3OH : CH2CI2, utilising 0.1 percent CH3OH increments) to yield the title compound 17 as a colourless crystalline solid (3.08 g, 6.51 mmol, 56 percent); RF = 0.29 (Silica, CH2CI2 - CH3OH, 9 : 1, v/v); 1H NMR (CDCI3, 500 MHz) δ 1.42 (18H, s, feoc CH3), 1.44 (9H, s, *Boc CH3), 2.81 (4H, br s, cyclen CH2), 3.28 (8H, br s, cyclen CH2), 3.60 (4H, br s, cyclen CH2); 13C NMR (CDCI3, 125 MHz, 1H decoupled 500 MHz) δ 28.9 (6C, 'Boc CH3), 29.0 (3C, 'Boc CH3), 46.1 (2C, cyclen CH2), 49.9 (2C, cyclen CH2), 51.2 (4C, cyclen CH2), 79.4 (2C, fex*,)), 79.6 (1C, ^oqq)), 155.8 (2C, feoc C = O), 156.0 (1C, 'Boc C = O); MS (ES+) m/z 473.3 (100 percent, [M + H]+); HRMS (ES+) m/z found 473.3330 [M + H]+ C23H45O6N4 requires 473.3333.
48% With triethylamine In chloroform at 0 - 20℃; for 20 h; Place the rotor in a 50 mL eggplant flask, dissolve 0.4649 g (2.703 mmol) of cyclen in 131.2 mL of CHCl 3, add 1.16 mmol of Et 3 N,Immersed in an ice bath and brought to 0 ° C.A solution of 1.780 g (8.213 mmol) of (Boc) 2 O in 10.1 mL of CHCl 3 was added dropwise at 0 ° C. over 2 hours. After the dropwise addition, the ice bath was removed and the mixture was stirred at room temperature for 18 hours.After this, the solution was washed three times with H 2 0 in a separating funnel,The organic phase was dried over Na 2 SO 4 and concentrated to give an oily substance which was vacuum dried to give a white solid. This solid was dissolved in a minimum amount of CHCl 3,Purification by open column chromatography (packing agent: silica gel, developing solvent: CHCl 3: MeOH = 20: 1) gave the fractions containing the desired product collected and concentrated to give the desired white solid(Yield 0.6133 g, 48percent).

Reference: [1] Journal of Materials Chemistry, 2012, vol. 22, # 36, p. 18784 - 18787
[2] Journal of the American Chemical Society, 2004, vol. 126, # 30, p. 9248 - 9256
[3] RSC Advances, 2016, vol. 6, # 28, p. 23645 - 23652
[4] Journal of Organic Chemistry, 2005, vol. 70, # 1, p. 115 - 123
[5] Chemical Communications, 2011, vol. 47, # 21, p. 6036 - 6038
[6] Tetrahedron, 2011, vol. 67, # 21, p. 3803 - 3808
[7] Angewandte Chemie - International Edition, 2006, vol. 45, # 32, p. 5340 - 5344
[8] Inorganica Chimica Acta, 2011, vol. 365, # 1, p. 38 - 48
[9] Journal of the American Chemical Society, 2011, vol. 133, # 51, p. 20704 - 20707
[10] Research on Chemical Intermediates, 2012, vol. 38, # 8, p. 2085 - 2096
[11] Angewandte Chemie - International Edition, 2006, vol. 45, # 17, p. 2745 - 2748
[12] Tetrahedron, 2006, vol. 62, # 24, p. 5748 - 5755
[13] Inorganic Chemistry, 2017, vol. 56, # 7, p. 3773 - 3780
[14] Journal of the American Chemical Society, 1997, vol. 119, # 13, p. 3068 - 3076
[15] Patent: US2008/193384, 2008, A1, . Location in patent: Page/Page column 4-5
[16] Patent: WO2014/153624, 2014, A1, . Location in patent: Page/Page column 42; 43
[17] Bulletin de la Societe Chimique de France, 1996, vol. 133, # 1, p. 65 - 73
[18] Chemistry - A European Journal, 2010, vol. 16, # 17, p. 5018 - 5025
[19] Advanced Synthesis and Catalysis, 2014, vol. 356, # 6, p. 1243 - 1254
[20] Patent: CN108047209, 2018, A, . Location in patent: Paragraph 0041; 0051; 0052
[21] Patent: WO2015/179955, 2015, A1, . Location in patent: Paragraph 00107; 00108; 00109
[22] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 18, p. 4542 - 4547
[23] Patent: WO2009/10580, 2009, A1, . Location in patent: Page/Page column 23; 30-31
[24] Patent: WO2010/84090, 2010, A1, . Location in patent: Page/Page column 43; 44
[25] Angewandte Chemie - International Edition, 2018, vol. 57, # 6, p. 1611 - 1615[26] Angew. Chem., 2018, vol. 130, # 6, p. 1627 - 1631,5
[27] Patent: JP2018/135304, 2018, A, . Location in patent: Paragraph 0041; 0042
[28] Synlett, 2004, # 3, p. 453 - 456
[29] Journal of Organic Chemistry, 2007, vol. 72, # 2, p. 376 - 385
[30] Bioorganic and Medicinal Chemistry, 2007, vol. 15, # 2, p. 696 - 701
[31] Bioorganic Chemistry, 2005, vol. 33, # 5, p. 374 - 385
[32] Chemistry and Biodiversity, 2009, vol. 6, # 8, p. 1273 - 1282
[33] Chemistry - A European Journal, 2010, vol. 16, # 43, p. 12935 - 12940
[34] Inorganica Chimica Acta, 2010, vol. 363, # 12, p. 2896 - 2904
[35] Frontiers of Chemistry in China, 2010, vol. 5, # 2, p. 184 - 192
[36] Journal of Coordination Chemistry, 2015, vol. 68, # 2, p. 335 - 349
[37] Patent: CN104478984, 2016, B, . Location in patent: Paragraph 0061-0063
  • 9
  • [ 24424-99-5 ]
  • [ 294-90-6 ]
  • [ 175854-39-4 ]
  • [ 913528-02-6 ]
Reference: [1] Tetrahedron Letters, 2006, vol. 47, # 39, p. 6937 - 6940
[2] Synthetic Communications, 2004, vol. 34, # 11, p. 2077 - 2084
  • 10
  • [ 5292-43-3 ]
  • [ 294-90-6 ]
  • [ 122555-91-3 ]
YieldReaction ConditionsOperation in experiment
83.5% With sodium hydrogencarbonate In acetonitrile at 0 - 20℃; for 49 h; Inert atmosphere 1,4,7,10-Tetraazacyclododecane (1 g, 5.81 mmol) was dissolved in dry acetonitrile (20 ml) under nitrogen at 0oC. NaHCO3 (1.464 g, 17.44 mmol) was added with stirring. tert-Butyl bromoacetate(3.4 g, 17.44 mmol) in 10 ml acetonitrile was added slowly from a dropping funnel in 1 h. The reaction was stirred at 0oC for another 3 h and at room temperature for 45 h. The progress of the reaction was monitored by TLC using dichloromethane (DCM):methanol (9:1) (Rf 0.67). On completion of reaction, reaction mixture was filtered and filtrate was evaporated to dryness. Crude compound was purified by column chromatography over silica gel using 2percent methanol in DCM as eluant to give compound 2 as white powder.Yield: 83.5percent
83% With potassium carbonate In acetonitrile at 70℃; for 6 h; (a) tert-butylbromoacetate, K2C03 (6 eq.), acetonitrile, 70°C, 6 hrs, 83percent
78% With sodium acetate In N,N-dimethyl acetamide at 0 - 20℃; for 120 h; In a 500 ml round bottom flask, the compound (1) (2 g, 11.62 mmol) and sodium acetate (2.85 g, 34.8 mmol) were dissolved in N, N-dimethylacetamide (DMA, 25 mL). Tert-butyl bromoacetate (6.79 g, 34.82 mmol) was dissolved in N, N-dimethylacetamide (10 mL) at 0 ° C under ice-cooling, and reacted at room temperature for 5 days, After the completion of the reaction and then pour 125ml of water, then the reaction will be slightly yellow solution, And then slowly add sodium bicarbonate, will find the reaction of white precipitate produced, The precipitate was filtered and the precipitate was dissolved in 150 mL of chloroform, and washed with water (3 x 100 mL), discard the aqueous phase. The organic phase was dried over sodium sulfate (Na2SO4) and concentrated under reduced pressure. The organic phase was recrystallized from diethyl ether to give the compound (2) (4.1 g, 78percent) as a white solid. Having a structure of the following formula 3:
77%
Stage #1: With triethylamine In chloroform for 2.5 h;
Stage #2: With potassium carbonate In chloroform for 14 h;
3.3 equivalents of tert-butyl bromoacetate (773.0 mg, 7.6 mmol) dissolved in 10.0 mL anhydrous chloroform was added dropwise to a mixture of 1,4, 7,10-tetraazacyclododecane (cyclen) (400.0 mg, 2.32 mmol) and 10.0 equivalents of triethylamine (2.3 g, 23.2 mmol) in 40 mL anhydrous chloroform under an argon atmosphere for about half an hour. The reaction mixture was stirred for another 2 hours, and 0.5 equivalents of anhydrous K2CO3 was added. After a further 14 hours of reaction, the resulting solution was washed by water (3 x 40 mL). Then anhydrous Na2SO4 was used to dry the organic phase and the solvent was removed under vacuum to give a transparent oil. This crude product was purified by flash chromatography on aluminium oxide (dichloromethane/methane = 200: 5 (volume/volume), Rf = 0.35) to give tris-(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane (1) as a white powder (0.92 g, 1.78 mmol), yield: 77percent. mp 178-180°C, 1H NMR (400 MHz, CDCl3) : δ 3.34 (4H, s), 3.26 (214, s), 3.05 (4H, s), 2.89-2. 85 (12H, m), 1.47 (27H, s) ; 13C NMR (100 MHz, CDCl3) : δ 170.5 (2 x C), 169.6 (C), 81.6 (3 x C), 58.2 (3 x CH2), 51. 3 (2 x CH2), 51. 1 (2 x CH2) 49.2 (2 x CH2), 47.5 (2 x CH2) 28.2 (3 x CH3) ; ESIMS m/z 515.3 (M+H)+; HRFABMS m/z 515. 3811 (M+H)+ [Calcd. For C26H51N4O6(M+H)+, 515.3809].
73% With sodium acetate In N,N-dimethyl acetamide at 0 - 20℃; for 120 h; Inert atmosphere Example 1-Synthesis of Tri-tert-butyl 2,2',2'-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
The protocol from O.
Axelsson et al in was used.
Cyclen (1,4,7, 10-tetraazacyclododecane) (5.0 g, 29 mmol) and AcONa (7.22 g. 88 mmol) were introduced in dry DMA (80 mL) under argon. α-bromo-tert-butylacetate (13 mL, 87 mmol) dissolved in dry DMA (13 mL) was added drop by drop at 0 °C and the reaction was performed at room temperature during 5 days.
At the end of the reaction, water (140 mL) was poured into the mixture and pH was adjusted at 9 with Na2CO3 before the introduction of KBr (5.05 g, 42.4 mmol).
The mixture was filtrated and the beige precipitate was solubilized in CH2Cl2 and water was extracted.
The organic layer was dried over Na2SO4, was concentrated, and the residue was washed with cooled EtOAc to isolate a white powder.
This purification process led to the isolation of tri-tert-butyl-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate as an amorphous white powder (10.9 g, 73 percent).
Mp : 179 °C (recrystallised from toluene to give yellow crystals).
Rf : 0.7 (CH2Cl2/MeOH/NH4OH 80:15:5, Draggendorf visualization)
1H NMR (CDCl3, 300 MHz) δ 3.36 (s, 4H, H8), 3.28 (s, 2H, H13), 3.07 (m, 4H, H6), 2.88 (m, 12H, H2, H3, H5), 1.46 (s, 18H, H12), 1.45 (s, 9H, H17).
13C NMR (CDCl3, 75 MHz) δ 170.7 (C9), 169.9 (C14), 81,9 (C16), 81.7 (C11), 58.3 (C8 - C13), 51.5 (C5), 49.6 (C2 - C3), 47.7 (C6), 28.4 (C17), 28.3 (C12).
MS (ESI+) : m/z 515 [M+H]+.
73% With sodium acetate In N,N-dimethyl acetamide at 0 - 20℃; for 120 h; Inert atmosphere The protocol from O. Axelsson et al in WO200612723 2006 was used. Cyclen (1,4,7,10-tetraazacyclododecane) (5.0 g, 29 mmol) and AcONa (7.22 g. 88 mmol) were introduced in dry DMA (80 mL) under argon, α-bromo-tert-butylacetate (13 mL, 87 mmol) dissolved in dry DMA (13 ml) was added drop by drop at 0 °C and the reaction was performed at room temperature during 5 days. At the end of the reaction, water (140 ml) was poured into the mixture and pH was adjusted at 9 with Na2CO3 before the introduction of KBr (5.05 g, 42.4 mmol). The mixture was filtrated and the beige precipitate was solubilized in CH2Cl2 and water was extracted. The organic layer was dried over Na2SO4, was concentrated, and the residue was washed with cooled EtOAc to isolate a white powder. This purification process led to the isolation of tri-tert-butyl-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate as an amorphous white powder (10.9 g, 73 percent). Mp : 179 °C (recrystallised from toluene to give yellow crystals). Rf : 0.7 (CH2Cl2/MeOH/NH4OH 80:15:5, Draggendorf visualization) 1H NMR (CDCl3, 300 MHz) δ 3.36 (s, 4H, H8), 3.28 (s, 2H, H13), 3.07 (m, 4H, H6), 2.88 (m, 12H, H2, H3, H5), 1 .46 (s, 18H, H12), 1 .45 (s, 9H, H17). 13C NMR (CDCl3, 75 MHz) δ 170.7 (C9), 169.9 (C14), 81 ,9 (C16), 81.7 (C11), 58.3 (C8 - C13), 51.5 (C5), 49.6 (C2 - C3), 47.7 (C6), 28.4 (C17), 28.3 (C12). MS (ESI+) : m/z 515 [M+H]+.
73% With sodium acetate In N,N-dimethyl acetamide at -20℃; for 24 h; To a suspension of cyclen (5.00 g, 29 mmol) and sodium acetate (7.86 g, 96 mmol) in DMA (60 mL) at -20 °C was added a solution of f-butyl bromoacetate (18.7 g, 14.1 mL, 96 mmol) in DMA (20 mL) dropwise over a period of 0.5 hour. The temperature was maintained at -20 °C during the addition, after which the reaction mixture was allowed to come to room temperature. After 24 hours of vigorous stirring, the reaction mixture was poured into water (300 mL) to give a clear solution. Solid KHCO3 (15 g, 1 50 mmol) was added portion wise, and compound 2 precipitated as a white solid. The precipitate was collected by filtration and dissolved in CHCI3 (250 mL). The solution was washed with water (100 mL), dried (MgSO4), filtered and concentrated to about 20-30 mL. Ether (250 mL) was added, after which compound 3 crystallized as a white fluffy solid. Yield: 1 2.5 g (73 percent). ESI-MS found: [M+H]+ = 515.5. 3
72% at 20℃; for 72 h; A solution of 2.20 equivalents of tert-butylbromoacetate in CHCl3 (40 ml) was added dropwise to a solution of one equivalent of tetraazacyclododecane in in CHCl3 and the solution was stirred at room temperature for 72 hours. The free protonated tetraazacyclododecane was then removed by filtration, and the resulting filtrate was washed with water and dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure yielding 72percent of tri-N-substituted tetraazacyclododecane 1, which was used for the next step without further purification. ESI-MS(+): found: 515 [M+H]+; calculated for C26H50N4O6: m/z 514, Rf = 0.64 (CHCl3/MeOH: 5:1), 1H NMR (250 MHz, CDCl3): 1.45 (s, 27H), 2.17 to 2.81 (m, 16H), 3.33 (s, 6H), 10.01 (br, 1 H); 13C NMR (CDCl3): 28.61 (C-16); 48.08 (C-9, C-11); 50.69 (C-2, C-6); 52.32(C-8, C-12); 53.02 (C-3, C-5); 57.21 (C-13); 80.74 (C15); 171.25, 171.41 (C-14a, C-14c). Elemental analysis: calculated (found) for: C26H50N4O6; C, 60.67(60.69); H, 9.79 (9.81); N, 10.89 (10.87); O, 18.65 (18.71). MS-MS of 515 in ESI mode: (El/intensity in percent) (Scheme 2): m/z= 459 (100percent); 409 (88percent), 347 (20percent).
64% With sodium acetate In N,N-dimethyl acetamide at 20℃; for 120 h; Cooling with ice Dissolve 2.0 g (11.6 mmol) starting material-1,4,7,10-tetraazacyclododecane in 25 ml dimethylacetamide and add 2.85 g (34.7 mmol) sodium acetate into the solution.
Place the mixture in a 0 t ice bath, add 6.9 g (35.6 mmol) tert-butyl bromoacetate drop by drop, and stir the mixture at room temperature for 5 days.
Then the mixture is poured into 125 ml water and add sodium bicarbonate into the mixed solution in batches.
A solid is obtained after filtration and then is dissolved in 150 ml chloroform and washed with 75 ml water.
Next get the organic layer, and add anhydrous sodium sulfate for dehydration. After vacuum evaporation for concentration and dissolution in 20 ml chloroform, add 150 ml alcohol for recrystallization to get 3.83 g (64.0percent) white solid product. The product is 1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane. Analytic data of 1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane: IR(KBr) ν 3980 (NH), 1730 and 1720 (C═O), 1162 and 1140 (CO) cm−1. 1H NMR (CDCl3) δ 10.05 (br, 1H, NH), 3.38 (s, 4H, CH2CO2), 3.29 (s, 2H, CH2CO2), 3.09 (s, 2H, NHCH2CH2), 2.91-2.88 (m, 8H, CH2CH2NHCH2CO2), 1.46 (s, 27H, (CH3)3). 13C NMR (CDCl3) δ 171.13 and 170.24 (CO). 82.28 (C(CH3)3), 58.80 (NCH2CO2), 51.92 and 51.80 (NCH2CH2N), 49.77 (NCH2CH2NH), 48.13 (NCH2CH2NH), 28.83 and 28.80 (C(CH3)3). MS m/z 515 ((M+H)+).
64% With sodium acetate In N,N-dimethyl acetamide at 0 - 20℃; for 120 h; Take 2.0 grams (g),11.6 millimol (mmol) of starting material 1,4,7,10-tetraazacyclododecane (1,4,7,10-tetraazacyclododecane) dissolved in 25 ml (ml) of dimethyl acetamidine In the case of dimethylacetamide,Then add 2.85 grams,34.7 milliliters of sodium acetate,Placed in a 0 degree ice bath,Add 6.9 grams dropwise,35.6 mmol of tert-butyl bromoacetate Moore (tert-butyl bromoacetate),Stir at room temperature for five days.Then, the aforementioned starting solution is poured into 125 ml of water.And add sodium bicarbonate in batches,After filtration, a solid is obtained.The above solid was dissolved in 150 ml of chloroform (Chloroform).And add 75 ml of water for cleaning.Next, take out the organic layer,Add anhydrous sodium sulfate to remove water,After concentration under reduced pressure, it was placed in 20 ml of chloroform.Recrystallization from 150 ml of ethanol,3.83 g of a 64.0percent white solid product are obtained as 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane.
48% With sodium hydrogencarbonate In acetonitrile at -5 - 20℃; for 24 h; A solution of cyclen S1 (2.90 g, 16.83 mmol), NaHCO3 (4.25 g, 50.59 mmol) and CH3CN (40 mL) was stirred at −5 °C before tert-butyl bromoacetate (7.6 mL, 51.47 mmol) was added dropwise. The reaction was slowly warmed to ambient temperature and stirring was maintained for 24 h. The thick white suspension was filtered under vacuum and the pale yellow filtrate was collected and concentrated under reduced pressure. The crude material was dissolved in hot PhMe (ca. 80 mL) and the desired product was isolated as the HBr salt using vacuum filtration. The white solid was dissolved in CH2Cl2 (50 mL) and washed with sat. NaHCO3 (3 × 40 mL), brine (40 mL), dried (Na2SO4), filtered and concentrated in vacuo to give the title compound (4.178 g, 48percent) as a white solid. m.p 187–188 °C. (lit. 190–191 °C). ADDIN EN.CITE Jagadish2011484484817Jagadish, BhumasamudramBrickert-Albrecht, Gayle L.Nichol, Gary S.Mash, Eugene A.Raghunand, NatarajanOn the synthesis of 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecaneTetrahedron LettersTetrahedron Letters2058-20615217SynthesisDOTADO3AContrast agentMRIX-ray crystallography20114/27/0040-4039http://www.sciencedirect.com.autorpa.lib.fju.edu.tw:2048/science/article/pii/S0040403910018630http://dx.doi.org.autorpa.lib.fju.edu.tw:2048/10.1016/j.tetlet.2010.10.0744 1H NMR (500 MHz, DMSO-d6) δ 8.78 (2H, br s, NH2), 3.41 (4H, s, 2 × CH2CO2), 3.35 (2H, s, CH2CO2), 3.02–2.96 (4H, m, 2 × CH2), 2.85–2.83 (4H, m, 2 × CH2), 2.71–2.66 (8H, m, 4 × CH2), 1.43–1.42 (27H, m, 9 × CH3). 13C NMR (125 MHz, DMSO-d6) δ 170.6 (2 × C), 170.0, 80.6, 80.5 (2 × C), 56.0 (2 × C), 52.1 (2 × C), 51.1, 49.6 (2 × C), 48.4 (2 × C), 45.5 (2 × C), 27.9 (6 × C), 27.8 (3 × C). HRMS (ESI, m/z) for C26H50N4O6 [M + H]+ calc. 515.3803; found 515.3810.
47% at 0 - 20℃; for 18.5 h; Reaction of cyclen with 3.0 eq of tert-butyl bromoacetate: (0169) To a solution of cyclen 1 (500 mg, 2.9 mmol) in anhydrous CHCl3 (5 mL) at 0° C. was added a solution of tert-butyl bromoacetate (1.70 g, 8.7 mmol) in anhydrous CHCl3 (10 mL) over 30 min. The resulting mixture was gradually warmed to rt, and continuously stirred for 18 h after which the reaction mixture was filtered while washing with CH2Cl2 to afford cyclen and mono-substituted cyclen (451 mg) as solid. The filtrate was concentrated in vacuo, and H2O (7 mL) was added into the residue, and the resulting solution was treated with 0.1 M HCl and 0.5 M NaOH to adjust the pH to 7. The resulting aqueous solution was evaporated, and the residue was dissolved in CH2Cl2 and filtered to remove NaCl salt. The filtrate was evaporated to dryness and the residue was washed with H2O to provide pure Compound 2 (696 mg, 47percent). The aqueous and ether layers were evaporated and dried to afford bi-substituted cyclen (115 mg, 9.9percent) and tetra-substituted cyclen (47 mg, 0.3percent), respectively. The 1H and 13C NMR spectra of Compound 2 were essentially identical to data reported previously. Reaction of cyclen with 2.4 eq of tert-butyl bromoacetate: (0170) To a solution of cyclen 1 (1.00 g, 5.8 mmol) in anhydrous CHCl3 (5 mL) at 0° C. was added a solution of tert-butyl bromoacetate (2.72 g, 13.95 mmol) in anhydrous CHCl3 (10 mL) over 30 min. The resulting mixture was stirred at 0° C. for 1 h, gradually warmed to rt, and continuously stirred for 17 h after which the reaction mixture was concentrated in vacuo. H2O (15 mL) was added into the residue, and pH of the resulting solution was adjusted to 7. Diethyl ether (15 mL) was added into the aqueous solution, and the white solid that formed was filtered off, washed with water, and dissolved in CH2Cl2. The organic solution was dried over MgSO4, filtered, and evaporated to the dryness to afford pure Compound 2 (1.34 g, 45percent). The 1H and 13C NMR spectra of Compound 2 were essentially identical to data reported previously.
36.5% With triethylamine In chloroformInert atmosphere 3.5 equiv. of appropriate tert-Butyl bromoacetate (1.2 mL, 7.6 mmol) dissolved in 10.0 mL of anhydrous chloroform was added dropwise to a mixture of 1,4,7,10-tetraazacyclododecane (cyclen) (400.0 mg, 2.32 mmol) and 10.0 equiv. triethylamine (2.3 g, 23.2 mmol) in 40 mL of anhydrous chloroform under N2. The reaction mixture was stirred for a further 16-20 h. The resulting solution was washed by water (40 mL×3), and the organic phase was dried by Na2SO4. The solvent was removed, and the crude products were purified by column chromatography on Al2O3 to afford the products 3 (437 mg, 36.5percent).
32% With sodium hydrogencarbonate In acetonitrile at 20℃; for 24 h; To a solution of tert-butyl bromoacetate (8.67 g, 44.23 mmol) in dry MeCN (75 cm3) was added cyclen (2.54 g, 14.70 mmol) and sodium hydrogen carbonate (3.72 g, <n="30"/>44.23 mmol). The reaction mixture was then stirred at room temperature under argon for 24 h. The solution was filtered and the filtrate solvent removed under reduced pressure to afford an orange residual oil, which crystallised upon standing. The crude material was purified by chromatography on silica gel (gradient elution: CH2Cl2: to 30percent CH2Cl2 / 60percent THF / 5percent MeOH / 5percent NH3) to yield the title compound as a white crystalline solid (2.41 g, 4.68 mmol, 32percent). δH (CDCI3, 500 MHz) 1.47 (27H, s, tBu), 2.88 (12H, br d, cyclen CH2), 3.11 (4H, br s, cyclen CH2), 3.30 (2H, s, acetate CH2),3.39 (4H, s, acetate CH2), 10.04 (1H, br s, NH). δc (CDCI3, 125 MHz) 28.4 (tBu), 30.6, 31.2, 47.8 (cyclen CH2), 49.4 (acetate CH2), 51.4 (cyclen CH2), 58.5 (acetate CH2), 81.9 (CtBu), 82.1(CtBu), 125.8, 169.9 (C=Oester), 170.8 (C=Oester). m/z (ES+) 515.6 (100percent, M + H).
32% With sodium hydrogencarbonate In acetonitrile at 20℃; for 24 h; Inert atmosphere This cyclen derivative was prepared according to the procedure described by O. Reany et al., J. Chem. Soc. Perkin. Trans 2., 2000, 1819. A mixture of cyclen (2.54 g, 14.7 mmol), te/t-butγl bromoacetate (8.67 g, 44.2 mmol) and NaHCO3 (3.72 g, 44.2 mmol) in anhydrous XH3CN (75 ml) was stirred at it, under argon, for 24 h. The solution was filtered and the filtrate concentrated under reduced pressure to afford a residual orange oil, which crystallised upon standing. The crude material was purified by column chromatography on silica (gradient elution: CH2CI2 to 5 percent CH3OH : CH2CI2, utilising 0.1 percent CH3OH increments) to yield the title compound 16 as a colourless crystalline solid (2.41 g, 4.68 mmol, 32 percent); m.p. 179-181 °C; 1H NMR (CDCI3, 500 MHz) δ 1.47 (27H, s, *Boc CH3), 2.88 (12H, br s, cyclen CH2), 3.11 (4H, br s, cyclen CH2), 3.30 (2H, s, CH2CO2^Bu), 3.39 (4H, s, CH2CO2^Bu), 10.04 (1H, br s, NH); 13C NMR (CDCI3, 125 MHz, 1H decoupled 500 MHz) δ 28.4 (9C, feoc CH3), 30.6- 31.2 (6C, cyclen CH2), 47.8 (1C, cyclen CH2), 49.4 (2C, CH2CO), 51.4 (1C, cyclen CH2), 58.5 (1C, CH2CO), 81.9 (2C, feoqq)), 82.1(1C, teoc(q)), 169.9 (2C, C = O), 170.8 (1C, C = O); MS (ES+) m/z 515.6 (100 percent, [M + H]+).

Reference: [1] Tetrahedron Letters, 2013, vol. 54, # 8, p. 918 - 920
[2] Tetrahedron Letters, 2009, vol. 50, # 31, p. 4459 - 4462
[3] European Journal of Medicinal Chemistry, 2013, vol. 65, p. 12 - 20
[4] Patent: WO2014/200872, 2014, A1, . Location in patent: Page/Page column 73; 77
[5] Organic and Biomolecular Chemistry, 2011, vol. 9, # 5, p. 1591 - 1599
[6] Journal of Drug Targeting, 2011, vol. 19, # 9, p. 761 - 769
[7] Dalton Transactions, 2013, vol. 42, # 14, p. 4994 - 5003
[8] Molecular Pharmaceutics, 2014, vol. 11, # 2, p. 445 - 456
[9] Journal of Medicinal Chemistry, 2010, vol. 53, # 18, p. 6747 - 6757
[10] Angewandte Chemie - International Edition, 2015, vol. 54, # 3, p. 1007 - 1010[11] Angew. Chem., 2015, vol. 127, # 3, p. 1021 - 1024,4
[12] Patent: TW2017/13632, 2017, A, . Location in patent: Paragraph 0012; 0015
[13] Patent: WO2005/3105, 2005, A1, . Location in patent: Page 8
[14] Chemistry - A European Journal, 2016, vol. 22, # 13, p. 4521 - 4527
[15] Journal of Materials Chemistry B, 2017, vol. 5, # 39, p. 8004 - 8012
[16] Journal of Labelled Compounds and Radiopharmaceuticals, 2012, vol. 55, # 4, p. 140 - 148
[17] Dalton Transactions, 2011, vol. 40, # 13, p. 3346 - 3351
[18] RSC Advances, 2016, vol. 6, # 9, p. 7288 - 7301
[19] Journal of the Chemical Society, Dalton Transactions, 2002, vol. 2, # 1, p. 48 - 54
[20] Patent: EP2740491, 2014, A1, . Location in patent: Paragraph 0123; 0124; 0125
[21] Patent: WO2014/86942, 2014, A1, . Location in patent: Page/Page column 31; 32
[22] Patent: WO2016/26841, 2016, A1, . Location in patent: Page/Page column 21
[23] Patent: EP1637524, 2006, A1, . Location in patent: Page/Page column 6
[24] Dalton Transactions, 2015, vol. 44, # 40, p. 17800 - 17809
[25] New Journal of Chemistry, 2016, vol. 40, # 5, p. 4606 - 4616
[26] New Journal of Chemistry, 2016, vol. 40, # 7, p. 5846 - 5854
[27] Dalton Transactions, 2007, # 45, p. 5260 - 5267
[28] Patent: US9981953, 2018, B1, . Location in patent: Page/Page column 8
[29] Patent: TW2018/13964, 2018, A, . Location in patent: Paragraph 0034; 0045; 0046; 0047
[30] Chemical Communications, 2007, # 12, p. 1269 - 1271
[31] Dalton Transactions, 2013, vol. 42, # 19, p. 6724 - 6727
[32] Chemistry - An Asian Journal, 2011, vol. 6, # 8, p. 1987 - 1991
[33] Inorganica Chimica Acta, 2017, vol. 462, p. 236 - 240
[34] Patent: US9115094, 2015, B2, . Location in patent: Page/Page column 51; 52
[35] Dalton Transactions, 2011, vol. 40, # 24, p. 6451 - 6457
[36] Journal of Pharmacy and Pharmacology, 2002, vol. 54, # 8, p. 1073 - 1081
[37] Chemical Communications, 2011, vol. 47, # 31, p. 8835 - 8837
[38] Inorganic Chemistry, 2017, vol. 56, # 14, p. 7960 - 7974
[39] Synthetic Communications, 2015, vol. 45, # 5, p. 661 - 672
[40] Patent: WO2009/10580, 2009, A1, . Location in patent: Page/Page column 28-29
[41] Patent: WO2010/84090, 2010, A1, . Location in patent: Page/Page column 40; 41
[42] Chemical Communications, 2003, # 13, p. 1550 - 1551
[43] Chemical Communications, 2005, # 2, p. 259 - 261
[44] Chemical Communications, 2006, # 8, p. 909 - 911
[45] Patent: US5679810, 1997, A,
[46] Patent: WO2006/112723, 2006, A1, . Location in patent: Page/Page column 14
[47] Patent: WO2006/60797, 2006, A2, . Location in patent: Page/Page column 14-15
[48] Inorganic Chemistry, 2012, vol. 51, # 4, p. 2325 - 2331
[49] Journal of the American Chemical Society, 2012, vol. 134, # 8, p. 3647 - 3650
[50] Tetrahedron Letters, 2014, vol. 55, # 38, p. 5294 - 5297
[51] Pharmaceutical Research, 2015, vol. 32, # 3, p. 955 - 967
[52] Patent: WO2015/89639, 2015, A1, . Location in patent: Paragraph 00221-00223
  • 11
  • [ 107-59-5 ]
  • [ 294-90-6 ]
  • [ 122555-91-3 ]
YieldReaction ConditionsOperation in experiment
36% With sodium hydrogencarbonate In acetonitrile at 20℃; for 40 h; To a mixture of 1,4,7,10-tetraazacyclododecane (cyclen) (2.00 g, 11 mmol) and NaHCO3 (3.22 g, 38.4 mmol) in CH3CN (80 mL) was added t-butyl chloroacetate (5.42 g, 36 mmol) and the resulting mixture was stirred at room temperature for 40 h. After filtration, the filtrate was concentrated in vacuo and CHCl3 was added to the residue. The insoluble materials were removed through a pad of celite and the solvent was evaporated. The crude product was recrystallized from toluene to yield DO3A(tBu)3. Yield: 2.0 g (36percent). 1H NMR (CDCl3, 270 MHz): d 1.46 (s, 9H), 1.47 (s, 18H), 2.89-2.92 (br, 12H), 3.09-3.11 (br, 4H), 3.30 (s, 2H), 6.26 (s, 1H), 3.38 (s, 4H).
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 24, p. 7410 - 7413
  • 12
  • [ 5292-43-3 ]
  • [ 294-90-6 ]
  • [ 137145-75-6 ]
  • [ 122555-91-3 ]
  • [ 507475-91-4 ]
Reference: [1] Patent: WO2005/32599, 2005, A1, . Location in patent: Page/Page column 22-24; figure 12
[2] Patent: WO2005/32599, 2005, A1, . Location in patent: Page/Page column 22-24; figure 12
  • 13
  • [ 5292-43-3 ]
  • [ 294-90-6 ]
  • [ 122555-91-3 ]
  • [ 507475-91-4 ]
Reference: [1] Patent: WO2005/3105, 2005, A1, . Location in patent: Page/Page column 6
[2] Patent: WO2005/3105, 2005, A1, . Location in patent: Page/Page column 6
[3] Patent: WO2005/3105, 2005, A1, . Location in patent: Page/Page column 6
[4] Patent: WO2005/3105, 2005, A1, . Location in patent: Page/Page column 6
  • 14
  • [ 5292-43-3 ]
  • [ 294-90-6 ]
  • [ 137145-75-6 ]
  • [ 122555-91-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 21, p. 5792 - 5795
  • 15
  • [ 5292-43-3 ]
  • [ 294-90-6 ]
  • [ 162148-48-3 ]
  • [ 122555-91-3 ]
  • [ 507475-91-4 ]
Reference: [1] Patent: WO2005/3105, 2005, A1, . Location in patent: Page/Page column 6
[2] Tetrahedron, 2004, vol. 60, # 26, p. 5595 - 5601
[3] Patent: WO2005/3105, 2005, A1, . Location in patent: Page/Page column 6
[4] Patent: WO2005/3105, 2005, A1, . Location in patent: Page/Page column 6
  • 16
  • [ 294-90-6 ]
  • [ 122555-91-3 ]
Reference: [1] Research on Chemical Intermediates, 2015, vol. 41, # 8, p. 5109 - 5119
  • 17
  • [ 5292-43-3 ]
  • [ 294-90-6 ]
  • [ 122555-91-3 ]
  • [ 507475-91-4 ]
Reference: [1] Patent: WO2005/3105, 2005, A1, . Location in patent: Page/Page column 6
Same Skeleton Products
Historical Records

Similar Product of
[ 294-90-6 ]

Chemical Structure| 10045-25-7

A789089[ 10045-25-7 ]

1,4,7,10-Tetraazacyclododecane tetrahydrochloride

Reason: Free-Salt